AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25952796
Drug: Sandwich-like neoadjuvant
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich-like neoadjuvant therapy with bevacizumab
Trial: 25954318
Drug: Maca root
RxNorm normalized name: maca root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca root (3.0 g/day)
Trial: 25954817
Drug: Home-based educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based educational intervention led by Community Health Representatives (CHRs) including a one hour group didactic session and monthly home-based educational interventions for 6 months.
Trial: 25955492
Drug: Chemotherapeutic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic and targeted agents
Trial: 25956795
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg orally once per day and depot octreotide at preprotocol dosage
Trial: 25956918
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive agent
Trial: 25957999
Drug: AZD3965 (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3965 (inhibitor of MCT1)
Trial: 25960972
Drug: Short-course IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course IV antibiotic treatment (ceftriaxone and metronidazole) for up to 5 days followed by 5 days of oral antibiotics
Trial: 25960972
Drug: Long-course IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course IV antibiotic treatment (between days 5 and 10)
Trial: 25961446
Drug: Dexcom G4
RxNorm normalized name: GLUCOSE SENSOR DEXCOM G4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexcom G4 Platinum CGM system (software 505) with hypoglycemic alert set at 80 mg/dL
Trial: 25962426
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg weekly in a 3-week cycle (MTD determined in Phase I)
Trial: 25962717
Drug: Sym004 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 (9 and 12 mg/kg weekly)
Trial: 25962728
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet (MedDiet) for men with elevated baseline hs-CRP (≥2 mg/l)
Trial: 25963722
Drug: BGG492 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 50 mg
Trial: 25963722
Drug: BGG492 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 100 mg
Trial: 25963722
Drug: BGG492 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 15 mg
Trial: 25963722
Drug: BGG492 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 (all doses)
Trial: 25963988
Drug: Micafungin 100
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg intravenous once daily
Trial: 25964244
Drug: AZD1775, 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775, 225 mg orally twice per day over 2.5 days per week for 2 weeks per 21-day cycle
Trial: 25964250
Drug: Adjuvant regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant regimen of gemcitabine (1,000 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed)
Trial: 25964296
Drug: Ofatumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (10 μg/mL)
Trial: 25964296
Drug: Ofatumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (10 mg/kg/dose)
Trial: 25964296
Drug: Rituximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (10 mg/kg/dose)
Trial: 25964643
Drug: Contemporary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contemporary radiation therapy in combined modality therapy
Trial: 25965712
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment for OSA
Trial: 25966740
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later.
Trial: 25968826
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy (IMRT 63 Gy/35 fractions, chemotherapy with paclitaxel 45 mg/m² and carboplatin AUC=2 for 7 weeks)
Trial: 25968826
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy
Trial: 25969178
Drug: Vaginal Gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Gel
Trial: 25969178
Drug: Oral Tablets
RxNorm normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: 25969833
Drug: Statistical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical model without pharmacodynamics
Trial: 25970800
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment cohorts
Trial: 25971886
Drug: Single-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose dexmedetomidine (DMT) 0.25 μg/kg in Group O (old age group)
Trial: 25971886
Drug: Single-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose dexmedetomidine (DMT) 0.35 μg/kg in Group Y (young age group)
Trial: 25971886
Drug: Single-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose dexmedetomidine (DMT)
Trial: 25972901
Drug: Vandetanib (67-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (67-150 mg/m²/day)
Trial: 25973150
Drug: Quercetin 250
RxNorm normalized name: quercetin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 250 mg capsules (bid)
Trial: 25975390
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol anesthesia clinically titrated by providers blinded to BIS
Trial: 25975390
Drug: Proposed maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proposed maintenance dosing regimen targeting BIS of 50 ± 10
Trial: 25975429
Drug: WPAI: SHP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPAI: SHP (daily activities impairment portion)
Trial: 25975934
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg telaprevir every 8 hours for 6 days
Trial: 25976268
Drug: PED-based smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PED-based smoking cessation intervention (counseling, referral to Quitline, free nicotine replacement therapy)
Trial: 25976768
Drug: Chemotherapy (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (first and second courses)
Trial: 25976768
Drug: Chemotherapy (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (multiple courses)
Trial: 25977266
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg once daily), asunaprevir (100 mg twice daily), peg-IFN/RBV after a 4-week lead-in phase with peg-IFN/RBV for a total of 24 weeks.
Trial: 25977884
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg once daily for 8 days)
Trial: 25979098
Drug: BIS-guided propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIS-guided propofol infusion
Trial: 25979230
Drug: Curcumin +
RxNorm normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin + FOLFOX chemotherapy
Trial: 25979786
Drug: Supportive text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive text messages (twice-daily for 3 months, then daily for 3 months)
Trial: 25979867
Drug: Telemedicine consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine consultation system for intravenous thrombolysis
Trial: 25980594
Drug: Vemurafenib 240-1120
RxNorm normalized name: vemurafenib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib 240-1120 mg or 960 mg orally twice daily
Trial: 25980594
Drug: Vemurafenib continued
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib continued after local therapy
Trial: 25980594
Drug: Vemurafenib treatment
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib treatment duration beyond initial PD
Trial: 25981814
Drug: Dovitinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (500 mg per day, orally, on a 5-days-on and 2-days-off schedule)
Trial: 25981813
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg oral capsules once a day on a continuous basis in 28-day cycles
Trial: 25982504
Drug: Methylcobalamin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin (30 mg/kg)
Trial: 25982654
Drug: Intravascular prosthesis
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular prosthesis implant
Trial: 25983041
Drug: SB939 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle
Trial: 25984876
Drug: Rapid intraarterial
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intraarterial treatment plus usual care
Trial: 25984880
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of antibiotics
Trial: 25984880
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of antibiotics
Trial: 25985404
Drug: Efavirenz-based antiretroviral
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based antiretroviral therapy (ART)
Trial: 25985404
Drug: Lopinavir-based antiretroviral
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir-based antiretroviral therapy (ART)
Trial: 25985870
Drug: Propofol as
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol as the sole induction agent
Trial: 25985870
Drug: Propofol as
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol as the primary maintenance agent
Trial: 25985870
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion rates
Trial: 25985870
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion duration
Trial: 25985870
Drug: Total doses
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total doses of propofol
Trial: 25985882
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) plus prednisone with concomitant bone-targeted therapy (BTT)
Trial: 25986244
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m2 weekly for 3 of 4 weeks
Trial: 25986244
Drug: Sorafenib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib and bortezomib combination
Trial: 25986244
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose level of sorafenib and bortezomib
Trial: 25986629
Drug: Threshold suspend
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold suspend (TS) feature of sensor-augmented insulin pump (SAP) therapy
Trial: 25987537
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIG) as an adjunct to standard treatment
Trial: 25987620
Drug: Cycloserine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, levofloxacin (750 mg) once daily, streptomycin (1 g) once daily
Trial: 25987620
Drug: Cycloserine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, moxifloxacin (400 mg) once daily, kanamycin (1 g) once daily
Trial: 25987791
Drug: Cholecalciferol 100000
RxNorm normalized name: cholecalciferol 100000 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 100000 IU per week for 4 weeks followed by 100000 IU per month in combination with PegIFN/RBV for 12 months.
Trial: 25988359
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) with clopidogrel
Trial: 25989179
Drug: White button
RxNorm normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White button mushroom (WBM) powder, dosage of 8 g/d and 14 g/d
Trial: 25989829
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) 400 mg for 8 weeks after switching from bPI or EFV
Trial: 25989973
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of FSFI during menstruation
Trial: 25989973
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of FSFI between menses
Trial: 25990577
Drug: LNG-IUS 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS 52 mg
Trial: 25991083
Drug: Faldaprevir 80
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 80 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Trial: 25991083
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Trial: 25993630
Drug: L-Arginine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine therapy (single dose and 6-week steady-state trial)
Trial: 25994816
Drug: Variant rs11668344-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variant rs11668344-G
Trial: 25995313
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (325 mg)
Trial: 25998039
Drug: ACE inhibitors/angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors/angiotensin receptor blockers
Trial: 25998042
Drug: Foretinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foretinib (various formulations including bisphosphate salt capsules, freebase tablets, and solution formulation)
Trial: 25998042
Drug: Foretinib (solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foretinib (solution formulation)
Trial: 25998717
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait therapy with the Lokomat® system (Intervention group, IG)
Trial: 25999106
Drug: iFR outside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iFR outside of treatment (≤0.85) and deferral (≥0.94) values
Trial: 25999183
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 325 mg pretreatment
Trial: 25999183
Drug: Slow dose
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow dose titration DMF
Trial: 25999435
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg (cohort 1)
Trial: 25999435
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg (cohorts 2 and 3)
Trial: 25999435
Drug: IPH2101 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPH2101 0.2 mg/kg (cohort 1)
Trial: 25999435
Drug: IPH2101 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPH2101 1 mg/kg (cohort 2)
Trial: 25999435
Drug: IPH2101 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPH2101 2 mg/kg (cohort 3)
Trial: 25999435
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lenalidomide and IPH2101
Trial: 25999444
Drug: Ruxolitinib, specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib, specific dosage and duration not available
Trial: 26001793
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to treatments including recombinant activated factor VII
Trial: 26003007
Drug: Regorafenib 60
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 60 mg/d continuously, Cisplatin 75 mg/m², Pemetrexed 500 mg/m² once every 21 days for up to 6 cycles.
Trial: 26006067
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 6 iv every 21 days and eribulin 1.4 mg/m2 on day 1 and day 8 every 21 days for four cycles
Trial: 26009269
Drug: Saracatinib 175mg
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 175mg orally daily
Trial: 26009994
Drug: siG12D-LODER™ plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siG12D-LODER™ plus chemotherapy
Trial: 26010778
Drug: HAI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI and systemic chemotherapy
Trial: 26011265
Drug: High Clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Clopidogrel dose
Trial: 26014957
Drug: Single-dose doripenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose doripenem (5 mg/kg for <8 weeks and 8 mg/kg for ≥8 weeks) administered intravenously over 1 h
Trial: 26014957
Drug: Single-dose doripenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose doripenem
Trial: 26015411
Drug: Oseltamivir 3
RxNorm normalized name: oseltamivir 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 3 mg/kg (cohort 1)
Trial: 26015411
Drug: Oseltamivir 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 2.5 mg/kg (cohort 2)
Trial: 26015411
Drug: Oseltamivir 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 2 mg/kg (cohort 3)
Trial: 26018967
Drug: DFMO (difluoromethylornithine)
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DFMO (difluoromethylornithine) 500-1500 mg/m2 orally twice a day for three weeks, followed by DFMO plus daily oral etoposide for additional three-week cycles.
Trial: 26020101
Drug: PHiD-CV (10-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine)
Trial: 26020125
Drug: Ceritinib 300
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 300 to 750 mg once daily in 21-day cycles
Trial: 26020125
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg once daily (maximum-tolerated dose)
Trial: 26020762
Drug: Quantitative Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quantitative Insulin Sensitivity Check Index (as a surrogate for hepatic insulin sensitivity)
Trial: 26020806
Drug: Cabazitaxel 20
RxNorm normalized name: cabazitaxel 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 20 mg/m plus Gemcitabine 1000 mg/m
Trial: 26020806
Drug: Cabazitaxel 15
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 15 mg/m plus Gemcitabine 900 mg/m
Trial: 26020806
Drug: Cabazitaxel 15
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 15 mg/m plus Gemcitabine 700 mg/m
Trial: 26020806
Drug: Gemcitabine 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 700 mg/m followed by Cabazitaxel 15 mg/m
Trial: 26020806
Drug: Cabazitaxel plus
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel plus Gemcitabine (all doses)